Upstream Biosciences develops drugs and diagnostic markers for cancer and infectious disease. Upstream optimizes disease treatment using chemical diversity analysis and genetic variation. Upstream has a proprietary approach to generate novel drug candidates and a data mining pipeline to determine genetic variations important to disease progression and drug response.

Upstream's current research is focused on two areas: the development of novel compounds for certain infectious diseases and the development of biomarkers for diagnosis and drug response. Upstream is currently engaged in the following research:

Preclinical Malaria Program
Upstream is collaborating with Alberta's Provincial Laboratory for Public Health for in vitro testing of Upstream's novel compounds against Malaria. Malaria is an infectious disease caused by protozoan parasites that are spread from person to person through the bites of infected mosquitoes. According to the World Heath Organization (WHO), about 40% of the world's population is at risk for Malaria.

Preclinical Trypanosomiasis (African Sleeping Sickness) Program
Upstream is collaborating with Makerere University in Kampala, Uganda, to begin toxicity testing of our novel compounds for the treatment of trypanosomiasis, or African Sleeping Sickness. Upstream's drug candidates for trypanosomiasis have demonstrated encouraging potential in vitro and may have application in both human and animal forms of the disease. According to the World Health Organization (WHO), an estimated 60 million people in sub-Saharan Africa are at risk of contracting this devastating condition spread by the tsetse fly. A 2002 United Nations report estimated that trypanosomiasis costs the economies of sub-Saharan Africa about $4.5 billion annually from lost farm income and increased malnutrition.

Cancer Biomarkers and Drug Response Assay
Upstream is collaborating with Genpathway and NimbleGen to identify and validate biomarkers important to disease progression and drug response. The companies bring together novel technology for identifying transcription factor binding sites. Genetic variations at these binding sites could be important for determining the course of disease treatment. Upstream intends to use these genetic variations as diagnostic markers for disease susceptibility and drug response. Upstream has filed a number of provisional patents for cancer biomarkers as well as an assay for determining biomarkers for drug response.

© 2006 Upstream Biosciences Inc. ~ all rights reserved

LEGAL NOTICE
The information provided through this website is intended solely for the general knowledge of visitors to the website and does not constitute an offer or a solicitation of an offer for the purchase or sale of any shares or other securities of Upstream Biosciences Inc.

NOTICE REGARDING FORWARD-LOOKING STATEMENTS
The information contained within this website contains “forward-looking statements”, as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this website, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: (i) the risk that that management is unable to execute the business plan; (ii) the risk that the company fails to obtain financing; (iii) the risk that the company’s patent applications are rejected by the USPTO or that, for whatever reason there is a failure to protect IP; (iv) the risk that key members of the management team leave or are terminated; and (iv) any other factor. These forward-looking statements are updated periodically. Although Upstream Biosciences Inc. believes that the beliefs, plans, expectations and intentions contained in this website are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth in this notice and should also refer to the risk factors disclosed in Upstream Bioscience Inc.’s periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.